Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Print this page Email this page Users Online: 147

  Table of Contents  
Year : 2019  |  Volume : 12  |  Issue : 6  |  Page : 554-555  

Oromandibular dystonia and botulinum neurotoxin: An overview

1 Department of Neurology, Federal University of Santa Maria, Santa Maria, Brazil
2 Department of Medicine, Federal University of Santa Maria, Santa Maria, Brazil

Date of Web Publication17-Oct-2019

Correspondence Address:
Jamir Pitton Rissardo
Department of Neurology, Federal University of Santa Maria, Santa Maria
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/mjdrdypu.mjdrdypu_254_19

Rights and Permissions

How to cite this article:
Rissardo JP, Fornari Caprara AL. Oromandibular dystonia and botulinum neurotoxin: An overview. Med J DY Patil Vidyapeeth 2019;12:554-5

How to cite this URL:
Rissardo JP, Fornari Caprara AL. Oromandibular dystonia and botulinum neurotoxin: An overview. Med J DY Patil Vidyapeeth [serial online] 2019 [cited 2022 Jul 2];12:554-5. Available from: https://www.mjdrdypv.org/text.asp?2019/12/6/554/269429

Dear Sir,

We read an article on “Medical Journal of Dr. D.Y. Patil University” with great interest. Shailaja et al. reported two cases of oromandibular dystonia (OMD) who were initially misdiagnosed, but later responded well to appropriate therapy. The first patient was diagnosed with dissociative motor disorder, and the other was without a clear diagnosis along a period of almost 2 years.[1]

Albanese et al. in 2013 defined dystonia as a movement disorder with sustained or intermittent muscle contractions causing abnormal, often repetitive, movements, postures, or both. In this context, OMD is a type of focal dystonia involving the mouth, jaw, and tongue causing involuntary jaw closure or opening, deviation of the jaw, facial grimacing, and tongue movements.[2]

We would like to address two recent systematic reviews with botulinum toxin (BoNT) in the management of OMD, which we think that together with the study of Shailaja et al. could lead to a better understanding of the treatment of this disorder.[1]

The study of Comella in 2018 concluded that the use of BoNT is not yet established and the studies available are single small controlled. She explained that the lack of large controlled studies could preclude any conclusion on the efficacy and safety of this medication. However, the available data suggest that BoNT may be the most effective treatment available and the more important medication to improve quality of life.[3]

In 2019, Dadgardoust et al. made a systematic review with meta-analysis. Their results showed that BoNT is efficacious in OMD by reducing dystonic movements and is generally considered a safe injection. Furthermore, they stated that their results with OMD are congruent with the BoNT for the previous data with focal dystonia.[4]

Based on these two reviews and other reports, we made a table with the type of OMD, injection site, recommended doses of BoNT, and possible adverse effects [Table 1]. We found some interesting characteristics in these reviews. First, Dadgardoust et al. found positive results, but the majority of the studies analyzed are single small controlled study, open-label observational studies, or retrospective chart reviews. Second, the majority of adverse effects reported with BoNT in OMD are related to formulation. We assumed that probably the continued improvements in the BoNT formulations and techniques lead to the markable decrease in the percentages of adverse effects from 62.2% to 2.38%. Third, we believe that both the rarity and the complexity of this movement disorder could influence in the previous data.[3],[4],[5]
Table 1: Type of oromandibular dystonia, injection site, recommended doses of botulinum toxin, and possible adverse effects

Click here to view

In summary, the case reported by Shailaja et al. puts in evidence important discussions about the OMD such as the socially embarrassing, misdiagnosis, and multiple consultations with different physicians. Therefore, case reports like this are essential for the awareness of rare diseases, mainly among general practitioners.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

  References Top

Shailaja B, Chaudhury S, Rohatgi S, Saldanha D. Oromandibular dystonia: A rare clinical entity. Med J Dr. DY Patil Vidyapeeth 2019 1;12:370.  Back to cited text no. 1
Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, et al. Phenomenology and classification of dystonia: A consensus update. Mov Disord 2013;28:863-73.  Back to cited text no. 2
Comella CL. Systematic review of botulinum toxin treatment for oromandibular dystonia. Toxicon 2018;147:96-9.  Back to cited text no. 3
Dadgardoust PD, Rosales RL, Asuncion RM, Dressler D. Botulinum neurotoxin a therapy efficacy and safety for oromandibular dystonia: A meta-analysis. J Neural Transm (Vienna) 2019;126:141-8.  Back to cited text no. 4
Jankovic J. An update on new and unique uses of botulinum toxin in movement disorders. Toxicon 2018;147:84-8.  Back to cited text no. 5


  [Table 1]

This article has been cited by
1 Hyperhidrosis, oromandibular dystonia, and botulinum toxin type a (Botox)
JamirPitton Rissardo, AnaLetícia Fornari Caprara
Medical Journal of Dr. D.Y. Patil Vidyapeeth. 2022; 0(0): 0
[Pubmed] | [DOI]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
   Article Tables

 Article Access Statistics
    PDF Downloaded117    
    Comments [Add]    
    Cited by others 1    

Recommend this journal